Company: CWAN
Filing Date: 2025-03-06
Form Type: S-4/A
Source: 0001193125-25-048570
Chunk: 67

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-06
Form: S-4/A
Chunk 67
---
Enfusion currently have relationships may terminate or otherwise reduce the scope of their relationship with either party in anticipation of the Transactions. Any such disruptions could limit the combined company’s ability to achieve the
anticipated benefits of the Transactions. The adverse effect of any such disruptions could also be exacerbated by a delay in the completion of the Transactions or by a termination of the Merger Agreement.

The combined company may be exposed to increased litigation, which could have an adverse effect on the combined company’s business, financial position, results of operations and cash flows.

The combined company may be exposed to increased litigation from stockholders,
customers, suppliers and other third parties due to the combination of Clearwater’s and Enfusion’s businesses following the Transactions. Such litigation may have an adverse impact on the combined company’s business, financial
position, results of operations and cash flows, or may cause disruptions to the combined company’s operations.

The financial forecasts are based on various assumptions that may not be realized.

The unaudited prospective financial information set forth in the forecasts
included under the section titled “The Transactions—Certain Financial Projections Utilized by the Special Committee and the Enfusion Board” was prepared solely for internal use and is subjective in many respects. Enfusion’s
prospective financial information was based solely upon assumptions of, and information available to, Enfusion’s management when prepared. These estimates and assumptions are subject to uncertainties, many of which are beyond Enfusion’s
control and may not be realized. Many factors mentioned in this Proxy Statement/Prospectus, including the risks outlined in this “Risk Factors” section and the events or circumstances described in the section titled “Cautionary
Statement Regarding Forward-Looking Statements” will be important in determining the combined company’s future results. As a result of these contingencies, actual future results may vary materially from Clearwater’s and
Enfusion’s estimates. In view of these uncertainties, the inclusion of prospective financial information in this Proxy Statement/Prospectus is not and should not be viewed as a representation that the forecasted results will necessarily reflect
actual future results.

The unaudited prospective financial information set forth in the forecasts included under the section titled
“The Transactions—Certain Financial Projections Utilized by the Special Committee and the Enfusion Board” was not prepared with a view toward compliance with published guidelines of the SEC or the guidelines established by the
American Institute of Certified Public Accountants for preparation or presentation of prospective financial information. Further, any forward-looking statement speaks only as of the date on which